Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Thrombosis Testing Coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedMutual of OmahaPolicy AHS-M2041

    Venous and Arterial Thrombosis Risk Testing

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS-M2041 alerts

    Get alerted when Policy AHS-M2041 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of laboratory testing for hereditary and acquired thrombophilia, including protein C, protein S, antithrombin III, Factor V Leiden, and prothrombin gene mutations. It applies to individuals evaluated for venous or selected arterial thrombotic events, subject to the stated clinical indications, limitations, and benefit coverage.

    Policy Summary
    PayerMutual of Omaha
    PolicyVenous and Arterial Thrombosis Risk Testing
    Policy CodePolicy AHS-M2041
    Change TypeModified
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionDocument the thrombotic event and the applicable clinical indication when requesting thrombophilia testing.
    SourceLink
    POLICY UPDATE CHANGES

    The former coverage criterion CC1.d was edited for clarity.

    The statement that assays for clotting inhibitor amount and function should be performed before molecular testing was removed from Note 1.

    6 weeksMinimum interval after acute thrombotic event
    2 weeksDeferral after stopping warfarin
    2 daysDeferral after stopping DOACs or heparin
    Not coveredActivated protein C resistance assay
    Not coveredPre-transplant DVT risk testing
    7Applicable procedure codes

    Coverage Criteria

    Protein C, protein S, and antithrombin III testing

    Covered when all of the following are met:

    Eligibility: The individual has no recurrent venous thromboembolism risk factors identified by the policy, such as surgery, prolonged immobilization, collagen vascular disease, malignancy, or certain hematologic disorders.

    At least one covered clinical situation

    • Young age with DVT or PE: The individual is younger than 50 years and has experienced any DVT or PE.<50 years
    • Unusual-site DVT: The individual has experienced DVT in an unusual site, such as the hepatic, mesenteric, or cerebral veins.
    Policy Summary
    PayerMutual of Omaha
    PolicyVenous and Arterial Thrombosis Risk Testing
    Policy CodePolicy AHS-M2041
    Change TypeModified
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionDocument the thrombotic event and the applicable clinical indication when requesting thrombophilia testing.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCoding and Diagnostic ParametersProvider Documentation and Action ItemsClinical BackgroundDefinitionsTiming and Frequency LimitsOrdering RequirementsNot Covered ServicesRevision History
    DVT with family history: The individual has experienced DVT and has a strong family history of thrombotic disease.
  1. DVT with pregnancy or oral contraceptive use: The individual has experienced DVT while pregnant or while taking oral contraceptives.
  2. Relative of young DVT patient: The individual is a first- or second-degree relative of a person who experienced DVT before age 50.
  3. Young woman who smokes and has myocardial infarction: The individual is a woman younger than 50 years who smokes and has suffered a myocardial infarction.Female and <50 years
  4. Targeted testing before oral contraceptives: The individual is being considered for oral contraceptive administration and has a personal or family history of DVT.
  5. Pediatric arterial ischemic stroke: The individual is a pediatric patient who has suffered arterial ischemic stroke.
  6. Protein C and protein S testing for specific conditions

    Covered when the applicable clinical condition is present.

    Specific indications

    • Warfarin-induced skin necrosis: The individual has warfarin-induced skin necrosis.
    • Neonatal purpura fulminans: The individual is an infant who develops neonatal purpura fulminans.

    Selected scenarios for thrombophilia testing

    Testing may be considered or conditionally supported when the clinical scenario and intended management impact justify it.

    Selected scenarios

    • VTE and thrombosis characteristics: VTE at an unusual site; pregnancy- or postpartum-associated VTE; oral-contraceptive-associated VTE; recurrent VTE; personal VTE with a relevant first- or second-degree family history or a first-degree relative with young-age VTE; or low activated protein C resistance activity.
    • Conditional scenarios: VTE associated with nonsurgical major transient or hormonal risk factors; cerebral or splanchnic venous thrombosis when anticoagulation would otherwise be discontinued; known familial antithrombin, protein C, or protein S deficiency when considering prophylaxis or avoiding estrogen; pregnancy with a family history of high-risk thrombophilia; or low- or intermediate-risk ambulatory cancer receiving systemic therapy with a family history of VTE.
    • Personal VTE or high-risk family history in women: A woman has a personal history of VTE or a first-degree relative with high-risk thrombophilia; potential testing includes Factor V Leiden, prothrombin G20210A, antithrombin, protein S, and protein C deficiency testing.

    Testing generally not recommended

    Testing is generally not recommended when it is unlikely to change management.

    Generally discouraged situations

    • VTE treatment-duration decisions: Do not test after unprovoked VTE or surgery-provoked VTE to determine anticoagulation duration. Testing may be considered after nonsurgical major transient-risk-factor VTE, pregnancy/postpartum VTE, or oral-contraceptive-associated VTE when results would guide treatment duration.
    • Asymptomatic or population testing: Do not perform testing in asymptomatic minors, for prenatal testing, or for population screening; do not test the general population before combined oral contraceptives or hormone replacement therapy.
    • Family testing: Testing is generally discouraged in asymptomatic relatives, relatives with known low-risk Factor V Leiden or prothrombin mutation, or relatives with unknown familial thrombophilia status unless a known high-risk familial deficiency and an actionable management decision are present.

    Venous thrombosis risk testing for superficial venous thrombosis, including superficial thrombophlebitis and varicosities, does not meet coverage criteria.

    The activated protein C resistance assay does not meet coverage criteria in any situation.

    DVT risk testing performed as part of a pre-transplant evaluation does not meet coverage criteria because published scientific literature confirming that the testing is required and beneficial for diagnosis and treatment is lacking.

    Prenatal testing and population screening for thrombophilia variants are not indicated because these variants have low penetrance, typically present later in life, and lack genotype-directed prophylaxis.

    Routine thrombophilia testing is not recommended for women from the general population who are considering combined oral contraceptives or hormone replacement therapy. Testing is also generally not recommended for women with a family history of VTE and known low-risk Factor V Leiden or prothrombin mutation when the result would be used to guide estrogen use.

    Asymptomatic family members contemplating estrogen generally should not undergo thrombophilia testing. An exception may apply when a first-degree relative has VTE and a known hereditary thrombophilia, and the test result would change the decision to use estrogen.

    Thrombophilia testing should not routinely be performed after provoked VTE, at the time of VTE diagnosis, during the initial 3-month course of anticoagulation, while anticoagulation continues, or in asymptomatic first-degree relatives. Selective testing may be considered only when the result is expected to change anticoagulation, prophylaxis, or hormone-related management.

    Thrombophilia testing is not recommended for arterial thrombosis, broad population screening, routine testing before oral contraceptives, hormone therapy, or prenatal care, or healthy-individual screening for Factor V Leiden or prothrombin mutations.

    A D-dimer result alone must not be used to rule out pulmonary embolism in a patient with high clinical probability. High-probability patients should proceed to appropriate imaging.

    DVT risk testing performed as part of a pre-transplant evaluation does not meet coverage criteria.

    Inherited thrombophilia screening is not recommended solely because of fetal loss or other adverse pregnancy outcomes, including abruption, preeclampsia, or fetal growth restriction. Evidence is insufficient that antepartum heparin prophylaxis prevents recurrence in these situations.

    Routine thrombophilia testing is generally not medically useful after provoked VTE or after unprovoked VTE when the result will not change management. Testing is also not routinely useful in asymptomatic relatives when results would not alter prophylaxis or treatment.

    MTHFR mutation analysis and fasting homocysteine testing are not recommended for thrombophilia assessment, prediction of adverse pregnancy outcomes, or evaluation of increased VTE risk.

    Routine Factor V Leiden or prothrombin 20210G>A testing is not medically necessary for adults with idiopathic VTE when the result will not alter secondary prophylaxis. It is also not medically necessary for asymptomatic adult family members when testing is intended to guide primary prophylactic anticoagulation.

    A thrombophilia test result alone should not determine the duration of anticoagulation. A negative result should not be interpreted as proof that the individual has no inherited thrombophilia.

    Covered Indications

    Plasma testing for protein C, protein S, and antithrombin III deficiency

    Covered when all of the following are met:

    Eligibility and timing

    • Listed clinical situations: The individual is younger than 50 years with DVT or PE; has unusual-site DVT; has DVT with strong family history; has DVT during pregnancy or oral contraceptive use; is a first- or second-degree relative of a person with DVT before age 50; is a woman younger than 50 who smokes and has myocardial infarction; is undergoing targeted testing before oral contraceptive administration with personal or family history of DVT; or has pediatric arterial ischemic stroke.

    Protein C and protein S testing

    Covered when at least one of the following is present:

    Specific clinical conditions

    • Warfarin-induced skin necrosis: The individual has warfarin-induced skin necrosis.
    • Neonatal purpura fulminans: The individual is an infant who develops neonatal purpura fulminans.

    Selected children with arterial ischemic stroke

    Testing may be considered in selected children with arterial ischemic stroke, particularly when:

    Clinical circumstances: The stroke has no identifiable cause, the child has a personal history of thrombosis, or a first-degree relative has a history of thrombosis.
    Repeat or defer non-DNA testing when needed: Protein, factor VIII, lipoprotein(a), or homocysteine testing performed during the acute stroke phase is deferred or repeated after the acute event; non-DNA testing may be repeated when the child is older to ensure adult protein levels have been attained.Protein C, protein S, antithrombin: at least 4–6 weeks; factor VIII may require up to 6 months

    Selected Factor V Leiden and prothrombin testing scenarios

    Testing for Factor V Leiden and factor II c.*97G>A may be considered or suggested when at least one of the following applies:

    Selected clinical scenarios: VTE occurred at an unusual site; VTE was provoked by pregnancy or postpartum status; VTE was associated with oral contraceptive use; the patient has personal VTE with a relevant first- or second-degree family history or a first-degree relative with young-age VTE; the patient has recurrent VTE; or the patient has low activated protein C resistance activity.

    Selected ASH-supported thrombophilia testing

    Testing may be considered when the scenario is clinically relevant and results would change prophylaxis, anticoagulation, or estrogen-related management.

    Selected clinical scenarios: VTE is associated with a nonsurgical major transient or hormonal risk factor; cerebral or splanchnic venous thrombosis is present and anticoagulation would otherwise be discontinued; there is known high-risk familial antithrombin, protein C, or protein S deficiency; pregnancy or postpartum management is affected by a high-risk familial thrombophilia; estrogen use is being considered in the setting of high-risk familial thrombophilia; or the patient has low- or intermediate-risk ambulatory cancer receiving systemic therapy with a family history of VTE.

    ACOG-supported testing in women with VTE or high-risk family history

    Inherited thrombophilia screening may be considered when:

    ACOG-supported situations

    • Personal VTE history testing panel: For a woman with personal VTE history, potential testing includes Factor V Leiden, prothrombin G20210A, antithrombin, protein S, and protein C deficiencies.

    Selected testing for unusual thrombosis or pregnancy morbidity

    Testing may be considered in selected patients when the evaluation is expected to affect diagnosis or management; routine testing is not supported.

    Selected clinical presentations

    • Potential targeted evaluations: Consider evaluation for antiphospholipid antibodies, JAK2 mutation, or paroxysmal nocturnal hemoglobinuria when the result may clarify the cause or alter management.

    Coding and Diagnostic Parameters

    Applicable CPT/HCPCS Procedure CodesCPT
    85300Clotting inhibitors or anticoagulants; antithrombin III, activity
    85301Clotting inhibitors or anticoagulants; antithrombin III, antigen assay
    85302Clotting inhibitors or anticoagulants; protein C, antigen
    85303Clotting inhibitors or anticoagulants; protein C, activity
    85305Clotting inhibitors or anticoagulants; protein S, total
    85306Clotting inhibitors or anticoagulants; protein S, free
    85307Activated Protein C (APC) resistance assay
    Applicable CPT/HCPCS Procedure CodesCPT
    85300Clotting inhibitors or anticoagulants; antithrombin III, activity
    85301Clotting inhibitors or anticoagulants; antithrombin III, antigen assay
    85302Clotting inhibitors or anticoagulants; protein C, antigen
    85303Clotting inhibitors or anticoagulants; protein C, activity
    85305Clotting inhibitors or anticoagulants; protein S, total
    85306Clotting inhibitors or anticoagulants; protein S, free
    85307Activated Protein C (APC) resistance assay
    Age-adjusted D-dimer threshold
    Patients younger than 50 years>500 mcg/L
    Patients 50 years or older> age × 10
    UseAge-adjusted threshold for positivity in suspected pulmonary embolism when a sensitive D-dimer assay is used
    D-dimer clinical probability use
    Eligible settingOutpatient or emergency-department patients
    Appropriate probabilityLow or intermediate clinical probability, or PE-unlikely status
    ExclusionNot recommended for patients with high clinical probability; proceed to imaging instead
    Repeat proximal compression ultrasound
    Initial studyProximal compression ultrasonography (CUS)
    Repeat interval5–7 days after a negative proximal CUS
    When to repeatWhen DVT remains possible or clinical probability remains likely
    Testing interval after anticoagulant discontinuation
    WarfarinWait 2 weeks after discontinuation
    Direct oral anticoagulantsWait 2 days after discontinuation
    HeparinWait 2 days after discontinuation
    Physiologic estradiol range during estrogen therapy
    Physiologic estradiol range100–200 pg/mL
    Upper limitLevels should not exceed the physiologic range
    Clinical contextApplies to individuals receiving estrogen therapy

    Provider Documentation and Action Items

    Documentation Required

    Document the Clinical Indication

    Document the qualifying thrombotic event and the applicable clinical indication before ordering plasma protein testing. Coverage may apply for an individual without recurrent VTE risk factors who has a qualifying DVT or PE, including selected age, site, family-history, pregnancy/OC, or relative-history circumstances.

    • Record the thrombotic event (DVT or PE), age, anatomic site, relevant family history, pregnancy or oral-contraceptive status, and other applicable indication.
    • Coverage includes certain individuals younger than 50 with DVT/PE, DVT at an unusual site, DVT with strong family history, DVT during pregnancy or OC use, and first- or second-degree relatives of a person with DVT before age 50.
    Documentation Required

    Confirm Timing and Anticoagulant Status

    For plasma protein C, protein S, and antithrombin III testing, document that testing is appropriately timed and that anticoagulants are not being used.

    • Perform testing at least six weeks after the acute thrombotic event.
    • Document absence of anticoagulant therapy at the time of testing.
    Note

    Consider Complementary Thrombophilia Testing

    When hereditary or acquired thrombophilia is suspected, consider complementary genetic testing in addition to plasma protein testing when the result may be clinically useful.

    • Consider Factor V Leiden testing.
    • Consider prothrombin gene G20210A mutation testing.
    Documentation Required

    Document Clinical Rationale and Management Impact

    Document the clinical rationale for testing and how the result is expected to change management. Testing should support a specific decision rather than provide reassurance or routine risk information.

    • Explain whether results could alter anticoagulation, future VTE prophylaxis, pregnancy-related prophylaxis, estrogen or contraceptive choices, family evaluation, or another treatment decision.
    • For patients with personal VTE histories, document the intended management impact of testing for Factor V Leiden, prothrombin mutation, protein C, protein S, or antithrombin deficiency.

    Unsupported block type: documentation

    Documentation Required

    Record Potentially Useful Clinical Features

    Testing is more likely to be clinically useful when the patient has features suggesting inherited thrombophilia and the result could change management.

    • Young age at VTE, particularly under 40–50 years.
    • Recurrent VTE or VTE associated with a weak provoking factor at a young age.
    • VTE at an unusual site, such as cerebral or splanchnic veins.
    • Strong personal or first-degree family history of VTE.
    • Pregnancy morbidity, pregnancy/postpartum VTE, or VTE associated with estrogen use, when the result would affect prophylaxis or hormone decisions.
    Documentation Required

    Document D-Dimer Clinical Context

    Before D-dimer testing or imaging for suspected PE or DVT, document the pretest probability using a validated clinical decision rule or an appropriately documented clinical assessment.

    • For suspected PE, document Wells, Geneva, PERC, or another validated approach and whether probability is low, moderate/unlikely, or high/likely.
    • Use a sensitive D-dimer assay to rule out PE or DVT only when the clinical algorithm supports it; document the applicable age-adjusted threshold for patients 50 or older.
    • Proceed to imaging when D-dimer is positive or pretest probability is high/likely; document the clinical findings supporting the pathway.
    Denial Risk

    Superficial Venous Thrombosis Testing Not Covered

    Venous thrombosis risk testing for superficial venous thrombosis does not meet coverage criteria.

    • Not covered for superficial thrombophlebitis.
    • Not covered for varicosities.
    Denial Risk

    Activated Protein C Resistance Assay Not Covered

    Activated protein C resistance assay does not meet coverage criteria in any situation.

    • Do not submit the aPC resistance assay as a covered test.
    Denial Risk

    Pre-Transplant Testing Not Covered

    DVT risk testing performed as part of a pre-transplant evaluation does not meet coverage criteria because published evidence does not establish that it is required and beneficial for diagnosis or treatment.

    • Do not order or submit DVT risk testing solely as part of pre-transplant evaluation.
    Denial Risk

    MTHFR Thrombophilia Testing Not Supported

    MTHFR variant testing is not supported for thrombophilia assessment.

    • Do not order MTHFR testing to evaluate thrombophilia or negative pregnancy outcomes.
    • The ACMG does not support MTHFR testing because the variants do not correlate with negative pregnancy outcomes; this position was reaffirmed in 2020 and 2025.
    Denial Risk

    Adverse Pregnancy Outcomes Alone Do Not Support Screening

    Inherited thrombophilia screening is not recommended for adverse pregnancy outcomes alone because evidence is insufficient that antepartum heparin prophylaxis prevents recurrence.

    • Do not screen solely for fetal loss, placental abruption, preeclampsia, or fetal growth restriction.
    • A personal history of VTE or a first-degree relative with high-risk thrombophilia represents a separate clinical consideration and should be documented when applicable.
    Denial Risk

    Avoid MTHFR and Homocysteine Testing

    MTHFR mutation analysis and fasting homocysteine testing are not recommended for negative pregnancy outcomes or increased VTE risk.

    • Do not use MTHFR or homocysteine testing to evaluate adverse pregnancy outcomes.
    • Do not use these tests to assess increased VTE risk.
    Denial Risk

    Avoid Routine FVL or Prothrombin Testing

    Do not perform routine Factor V Leiden or prothrombin mutation testing in the populations addressed by the EGAPP recommendation.

    • Routine testing is not recommended for adults with idiopathic VTE when the result would not change secondary prophylaxis.
    • Routine testing is not recommended for asymptomatic adult family members of patients with VTE and an FVL or prothrombin mutation when considering primary prophylactic anticoagulation.
    • Limited exceptions may require individualized assessment, such as evaluating FVL homozygosity or counseling about antithrombotic therapy.
    Denial Risk

    Avoid Routine Thrombophilia Testing After VTE

    Follow Anticoagulation Forum guidance against routine thrombophilia testing after VTE unless a specific result could change a management decision.

    • Do not test after provoked VTE; a positive result does not justify extended anticoagulation.
    • Do not routinely test after unprovoked VTE; consider testing only when a patient plans to stop anticoagulation and the result would change that decision.
    • Do not test asymptomatic family members, including those considering estrogen, unless a known familial thrombophilia result would change estrogen or prophylaxis decisions.
    Denial Risk

    Avoid Routine or Poorly Timed Testing

    Discourage thrombophilia testing when it is performed at diagnosis, during anticoagulation, or without a management purpose because results may be inaccurate or clinically unhelpful.

    • Do not test at the time of VTE diagnosis or during the initial three months of anticoagulant therapy.
    • When testing is indicated, use staged testing or wait until at least three months of anticoagulant therapy is completed and anticoagulants are held; follow assay-specific washout guidance.
    • Do not use a negative result alone to stop anticoagulation or a positive result alone to determine duration of therapy.
    Denial Risk

    Avoid Screening and Other Low-Utility Indications

    Do not use thrombophilia testing for arterial thrombosis, broad population screening, or VTE strongly explained by a provoking factor unless a specific exception is documented.

    • Thrombophilia testing is not recommended for arterial thrombosis.
    • Do not include thrombophilia testing in broad population, prenatal, or routine pre-oral-contraceptive or hormone-therapy screening.
    • Do not use Factor V Leiden or prothrombin mutation testing as a screening tool in healthy individuals.
    • Testing may be considered in a narrowly defined asymptomatic woman with a first-degree relative with known thrombophilia and VTE who is pregnant, planning pregnancy, or considering hormonal contraception, only when results would alter prophylaxis or contraceptive decisions.
    Denial Risk

    Limit Routine Genetic Screening

    Do not perform routine genetic thrombophilia screening in asymptomatic individuals or family members. Consider targeted testing only when a documented familial or clinical circumstance makes the result likely to change management.

    • Avoid routine testing of asymptomatic minors, asymptomatic adult relatives, healthy individuals, and the general population.
    • Routine screening before combined oral contraceptives, hormone therapy, pregnancy, or prenatal care is not appropriate.
    • A limited exception may apply for a first-degree relative with known high-risk thrombophilia when the individual is considering estrogen, pregnancy, or hormonal contraception and the result would change prophylaxis or contraceptive decisions.
    • Document the specific family mutation or high-risk thrombophilia and the intended management change.

    Clinical Background

    Thrombophilia refers to hereditary or acquired abnormalities of hemostasis that predispose an individual to thrombosis. Venous thromboembolism most commonly presents as deep vein thrombosis or pulmonary embolism, although thrombosis may also occur in arterial vessels. Common inherited factors include Factor V Leiden, prothrombin mutations, and deficiencies of protein C, protein S, or antithrombin; acquired risks include surgery, immobilization, malignancy, pregnancy, oral contraceptive use, antiphospholipid syndrome, and other medical conditions.

    Definitions

    Venous thrombosis
    DefinitionA blood clot that blocks a vein
    Primary presentationVenous thromboembolism commonly presents as deep vein thrombosis or pulmonary embolism
    Thrombus locationOccurs within the venous blood vessels
    Arterial thrombosis
    DefinitionA blood clot that blocks an artery
    Blood vessel typeArterial blood vessel
    DistinctionArterial thrombosis is distinct from venous thrombosis, which blocks a vein
    Venous thromboembolism
    AbbreviationVTE
    DefinitionA venous thromboembolic condition that includes deep vein thrombosis and pulmonary embolism
    Included conditionsDeep vein thrombosis and pulmonary embolism
    Deep vein thrombosis
    AbbreviationDVT
    DefinitionA thrombus located in a deep vein
    Common locationThe lower extremity
    Pulmonary embolism
    AbbreviationPE
    DefinitionObstruction of the pulmonary artery or one of its branches by foreign material
    Common causeAn embolized thrombus
    First-degree relatives
    DefinitionParents, full siblings, and children of the individual
    Included relativesParents
    Included relativesFull siblings and children
    Second-degree relatives
    DefinitionGrandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings of the individual
    Included relativesGrandparents, aunts, and uncles
    Included relativesNieces, nephews, grandchildren, and half-siblings
    FVL
    AbbreviationFVL
    MeaningFactor V Leiden
    CategoryInherited thrombophilia risk factor
    PGM
    AbbreviationPGM
    MeaningProthrombin 20210A gene mutation
    CategoryInherited thrombophilia risk factor
    Pediatric AIS
    AbbreviationAIS
    DefinitionArterial ischemic stroke occurring in a child or neonate
    PopulationChildren or neonates
    FVL mutation
    AbbreviationFVL
    DefinitionFactor V Leiden mutation
    Testing contextFactor V Leiden testing is addressed in selected VTE and familial-risk scenarios
    PGM
    AbbreviationPGM
    DefinitionProthrombin gene mutation
    Alternate terminologyProthrombin 20210A or PGM
    PTP
    AbbreviationPTP
    DefinitionPretest probability or prevalence category used to select diagnostic testing strategies
    Clinical useUsed to determine whether D-dimer testing or imaging is appropriate
    GAHT
    AbbreviationGAHT
    DefinitionGender-affirming hormone therapy, particularly estrogen-based therapy
    Thrombotic contextEstrogen-based therapy may increase thrombotic risk; transdermal options carry the lowest VTE risk
    Venous thromboembolism
    AbbreviationVTE
    DefinitionA venous thromboembolism involving a deep vein or pulmonary artery
    Recurrence and treatment contextRisk and treatment decisions are strongly influenced by whether the event was provoked or unprovoked
    Pretest probability
    AbbreviationPTP
    DefinitionA clinical estimate of the likelihood of PE or DVT before laboratory or imaging testing
    Assessment toolsWells, Geneva, PERC, or clinical judgment
    D-dimer
    DefinitionA fibrin degradation marker
    Diagnostic useUsed with clinical probability assessment to help exclude PE or DVT in selected patients
    Testing limitationA positive D-dimer alone should not diagnose PE or DVT

    Timing and Frequency Limits

    Protein and factor testing after acute stroke
    Tests affectedProtein C, protein S, and antithrombin
    Timing after acute strokeDefer or repeat testing at least 4–6 weeks after the acute stroke
    Factor VIIIMay require deferral for up to 6 months
    Non-DNA thrombophilia tests and homocysteine
    TestsNon-DNA thrombophilia tests and homocysteine
    ChildrenRepeat non-DNA testing when the child is older to ensure adult protein levels have been attained
    Acute strokeTesting during the acute phase may be inaccurate and should be repeated after the acute event
    Thrombophilia testing after VTE
    Initial anticoagulation courseDo not perform testing during the initial 3-month course of anticoagulant therapy
    While anticoagulatedDo not test while the patient remains anticoagulated
    When indicated after VTETest after at least 3 months of therapy have been completed and anticoagulants have been held
    Testing after anticoagulant discontinuation
    WarfarinWait 2 weeks after discontinuation
    Direct oral anticoagulantsWait 2 days after discontinuation
    HeparinWait 2 days after discontinuation
    Compression ultrasonography for suspected DVT
    Likely DVT with negative proximal CUSRepeat proximal CUS in 5–7 days
    Negative whole-leg CUSNo repeat CUS or D-dimer is required
    Initial testing for likely DVTUse proximal CUS or whole-leg CUS as the first-line test

    Ordering Requirements

    Note

    Obtain specialist input and document medical necessity

    Seek specialist advice before considering thrombophilia testing in patients with DVT or PE. Order testing in the context of a documented clinical probability assessment and an expected management consequence.

    • Document the clinical probability assessment.
    • Document how the result could affect treatment, prophylaxis, or hormone and contraceptive decisions.

    Not Covered Services

    The following services do not meet coverage criteria: venous thrombosis risk testing for superficial venous thrombosis, superficial thrombophlebitis, or varicosities; the activated protein C resistance assay in all situations; and DVT risk testing performed as part of a pre-transplant evaluation.

    Revision History

    The policy was reviewed and updated effective March 18, 2026, with an effective date of November 1, 2026. The background, guidelines and recommendations, and evidence-based scientific references were updated. Former coverage criterion CC1.d was edited for clarity. The statement that assays for clotting-inhibitor amount and function should be performed before molecular testing was removed from Note 1.